SHAREHOLDER NOTICE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: ARQL, BOLD, THOR

BALA CYNWYD, PA / ACCESSWIRE / December 23, 2019 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions. If you own shares of any of the below-referenced stocks and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, or calling toll free 877-534-2590. There is no cost or financial obligation to you.

ARQULE, INC. (NasdaqGS:ARQL)

Under the terms of the agreement, ArQule shareholders will receive only $20.00 for each share of ArQule common stock owned. The investigation concerns whether the ArQule Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Merck is underpaying for the Company. For example, ArQule's lead new drug candidate under development, called ARQ 531, is a potential treatment of B-cell malignancies including relapsed or refractory chronic lymphocytic leukemia. Merck's President commented, "ArQule's focus on precision medicine has yielded multiple clinical-stage oral kinase inhibitors that have novel and important properties, …. This acquisition strengthens Merck's pipeline with the addition of these strategic assets."

Additional information can be found at http://www.brodskysmith.com/cases/arqule-inc-nasdaqgs-arql/, or call 877-534-2590. No cost or obligation to you.

AUDENTES THERAPEUTICS, INC. (NasdaqGS:BOLD)

Under the terms of the agreement, Audentes shareholders will receive only $60.00 for each share of Audentes common stock owned. The investigation concerns whether the Audentes Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Astellas Pharma, Inc.is underpaying for the Company. The transaction may undervalue the Company. For example, the merger will provide Astellas with Audentes robust pipeline, including its lead program AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM).

Additional information can be found at http://www.brodskysmith.com/cases/audentes-therapeutics-inc-nasdaqgs-bold/, or call 877-534-2590. No cost or obligation to you.

SYNTHORX, INC. (NasdaqGS:THOR)

Under the terms of the agreement, Synthorx shareholders will receive only $68.00 for each share of Synthorx common stock owned. The investigation concerns whether the Synthorx Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Sanofi is underpaying for the Company. For example, the drug at the center of the deal is Synthorx's investigational medicine code-named THOR-707. Meant to treat solid tumors, the drug is designed to boost the number of cancer-fighting cells in the body, potentially overwhelming the disease with effector T-cells and natural killer cells.

Additional information can be found at http://www.brodskysmith.com/cases/synthorx-inc-nasdaqgs-thor/, or call 877-534-2590. No cost or obligation to you.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC

ReleaseID: 571246